DE69333287D1 - Neuartige glykoformen als lösliche komplement-rezeptoren - Google Patents
Neuartige glykoformen als lösliche komplement-rezeptorenInfo
- Publication number
- DE69333287D1 DE69333287D1 DE69333287T DE69333287T DE69333287D1 DE 69333287 D1 DE69333287 D1 DE 69333287D1 DE 69333287 T DE69333287 T DE 69333287T DE 69333287 T DE69333287 T DE 69333287T DE 69333287 D1 DE69333287 D1 DE 69333287D1
- Authority
- DE
- Germany
- Prior art keywords
- glycoforms
- scr1
- innovative
- soluble complement
- complement receptors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/927,099 US5456909A (en) | 1992-08-07 | 1992-08-07 | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
US927099 | 1992-08-07 | ||
PCT/US1993/007406 WO1994003603A1 (en) | 1992-08-07 | 1993-08-06 | Novel glycoforms of soluble complement receptor 1 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69333287D1 true DE69333287D1 (de) | 2003-12-11 |
DE69333287T2 DE69333287T2 (de) | 2004-09-23 |
Family
ID=25454172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69333287T Expired - Lifetime DE69333287T2 (de) | 1992-08-07 | 1993-08-06 | Neuartige glykoformen als lösliche komplement-rezeptoren |
Country Status (15)
Country | Link |
---|---|
US (3) | US5456909A (de) |
EP (1) | EP0656061B1 (de) |
JP (1) | JP3662250B2 (de) |
CN (1) | CN1089951A (de) |
AT (1) | ATE253591T1 (de) |
CA (1) | CA2141842C (de) |
DE (1) | DE69333287T2 (de) |
DK (1) | DK0656061T3 (de) |
ES (1) | ES2210241T3 (de) |
IL (1) | IL106558A (de) |
MX (1) | MX9304800A (de) |
PT (1) | PT656061E (de) |
TW (1) | TW386878B (de) |
WO (1) | WO1994003603A1 (de) |
ZA (1) | ZA935728B (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
CA2162600C (en) * | 1993-05-17 | 2000-07-11 | Chrales W. Rittershaus | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
DE69534701T2 (de) | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | Verfahren zur behandlung von entzündlichen gelenkerkrankungen |
GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
US7112327B2 (en) * | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
KR100425965B1 (ko) * | 1998-02-20 | 2004-04-06 | 타녹스 인코퍼레이티드 | 보체 활성화의 억제물질 |
SE0004808D0 (sv) * | 2000-12-20 | 2000-12-20 | Apbiotech Ab | Method for the purification of an enzyme |
US20040214228A9 (en) * | 2001-09-14 | 2004-10-28 | Ganesh Venkataraman | Methods of evaluating glycomolecules for enhanced activities |
EP1438387A4 (de) * | 2001-09-14 | 2004-10-13 | Momenta Pharmaceuticals Inc | Verfahren zur herstellung von glycomolekülen mit verstärkten aktivitäten und verwendungen davon |
WO2004094823A2 (en) | 2003-04-23 | 2004-11-04 | Biovalve Technologies, Inc. | Hydraulically actuated pump for long duration medicament administration |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
JP4507682B2 (ja) * | 2004-04-26 | 2010-07-21 | 三菱化学株式会社 | 糖鎖分離方法、検体分析方法、液体クロマトグラフィー装置、並びに糖鎖分析方法及び糖鎖分析装置 |
US20090028850A1 (en) * | 2004-05-14 | 2009-01-29 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
EP1738763A1 (de) | 2005-06-30 | 2007-01-03 | AVANT Immunotherapeutics, Inc. | Verwendung eines Komplement-inhibierenden Proteins zur Behandlung von Rückenmarksverletzungen |
US20070004625A1 (en) * | 2005-06-30 | 2007-01-04 | Li Liang-Man | Use of complement inhibitory proteins to treat spinal cord injury |
GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
CA2624393C (en) * | 2005-11-04 | 2016-01-05 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
EP1969007B1 (de) | 2005-12-20 | 2013-08-28 | Bristol-Myers Squibb Company | Zusammensetzungen und verfahren zur herstellung einer zusammensetzung |
WO2007103134A2 (en) * | 2006-03-02 | 2007-09-13 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
HUE026496T2 (en) * | 2006-03-08 | 2016-06-28 | Archemix Llc | Complement-binding aptamers and anti-C5 agents for treating eye diseases |
AU2007225044C1 (en) | 2006-03-15 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
US7914499B2 (en) | 2006-03-30 | 2011-03-29 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
EP2913342A1 (de) | 2006-09-05 | 2015-09-02 | Alexion Pharmaceuticals, Inc. | Zusammensetzungen zur behandlung von antikörpervermittelten neuropathien |
CA2666843C (en) * | 2006-10-20 | 2015-06-16 | Celldex Therapeutics, Inc. | Treatment of age-related macular degeneration and other diseases of the eye |
MY157948A (en) * | 2006-11-02 | 2016-08-30 | Genentech Inc | Humanized anti-factor d antibodies |
LT3597659T (lt) | 2007-07-09 | 2023-05-10 | Genentech, Inc. | Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
KR20120027055A (ko) * | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
BR112012025645A2 (pt) | 2010-04-07 | 2017-12-12 | Momenta Pharmaceuticals Inc | glicanos de alta manose. |
CN107661491A (zh) * | 2010-09-15 | 2018-02-06 | 赛尔戴克斯治疗公司 | 用可溶性I型补体受体(sCR1)治疗慢性肾病 |
US9649356B2 (en) | 2010-10-27 | 2017-05-16 | Celldex Therapeutics, Inc. | Method of improving transplant function using soluble complement receptor type I (sCR1) |
EP2686671A4 (de) | 2011-03-12 | 2015-06-24 | Momenta Pharmaceuticals Inc | N-acetylhexosamin-haltige n-glykane in glycoproteinprodukten |
WO2013013193A1 (en) * | 2011-07-20 | 2013-01-24 | Zepteon, Incorporated | Polypeptide separation methods |
EP2856159A4 (de) | 2012-06-01 | 2016-04-13 | Momenta Pharmaceuticals Inc | Verfahren im zusammenhang mit denosumab |
US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
CR20160132A (es) | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
CA2944712A1 (en) | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
JP2018534930A (ja) | 2015-10-30 | 2018-11-29 | ジェネンテック, インコーポレイテッド | 抗d因子抗体及びコンジュゲート |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
US20210238238A1 (en) * | 2018-05-16 | 2021-08-05 | Csl Limited | Soluble complement receptor type i variants and uses thereof |
EP3581203A1 (de) * | 2018-06-11 | 2019-12-18 | Laboratoire Français du Fractionnement et des Biotechnologies | Antikörper mit erhöhter aktivität im verdauungstrakt |
WO2023240322A1 (en) * | 2022-06-17 | 2023-12-21 | CSL Innovation Pty Ltd | Purification of soluble complement receptor and variants thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212071A (en) * | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
US5079353A (en) * | 1987-12-02 | 1992-01-07 | Chembiomed, Ltd. | Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation |
IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification |
US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
WO1992010205A1 (en) * | 1990-12-06 | 1992-06-25 | T Cell Sciences, Inc. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
-
1992
- 1992-08-07 US US08/927,099 patent/US5456909A/en not_active Expired - Lifetime
-
1993
- 1993-08-02 IL IL10655893A patent/IL106558A/en not_active IP Right Cessation
- 1993-08-06 ES ES93918681T patent/ES2210241T3/es not_active Expired - Lifetime
- 1993-08-06 DK DK93918681T patent/DK0656061T3/da active
- 1993-08-06 PT PT93918681T patent/PT656061E/pt unknown
- 1993-08-06 ZA ZA935728A patent/ZA935728B/xx unknown
- 1993-08-06 WO PCT/US1993/007406 patent/WO1994003603A1/en active IP Right Grant
- 1993-08-06 CA CA002141842A patent/CA2141842C/en not_active Expired - Lifetime
- 1993-08-06 EP EP93918681A patent/EP0656061B1/de not_active Expired - Lifetime
- 1993-08-06 MX MX9304800A patent/MX9304800A/es unknown
- 1993-08-06 JP JP50558194A patent/JP3662250B2/ja not_active Expired - Lifetime
- 1993-08-06 DE DE69333287T patent/DE69333287T2/de not_active Expired - Lifetime
- 1993-08-06 AT AT93918681T patent/ATE253591T1/de not_active IP Right Cessation
- 1993-08-07 CN CN93117624A patent/CN1089951A/zh active Pending
-
1994
- 1994-01-21 TW TW082108937A patent/TW386878B/zh not_active IP Right Cessation
-
1995
- 1995-06-06 US US08/470,867 patent/US5858969A/en not_active Expired - Lifetime
-
1998
- 1998-11-05 US US09/186,827 patent/US6057131A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5858969A (en) | 1999-01-12 |
IL106558A0 (en) | 1993-12-08 |
WO1994003603A1 (en) | 1994-02-17 |
AU670453B2 (en) | 1996-07-18 |
CN1089951A (zh) | 1994-07-27 |
CA2141842C (en) | 2008-07-29 |
EP0656061B1 (de) | 2003-11-05 |
ZA935728B (en) | 1994-03-03 |
DK0656061T3 (da) | 2004-03-15 |
JP3662250B2 (ja) | 2005-06-22 |
ES2210241T3 (es) | 2004-07-01 |
US6057131A (en) | 2000-05-02 |
MX9304800A (es) | 1994-05-31 |
EP0656061A1 (de) | 1995-06-07 |
IL106558A (en) | 1998-10-30 |
DE69333287T2 (de) | 2004-09-23 |
PT656061E (pt) | 2004-03-31 |
US5456909A (en) | 1995-10-10 |
JPH08501773A (ja) | 1996-02-27 |
ATE253591T1 (de) | 2003-11-15 |
TW386878B (en) | 2000-04-11 |
AU4804193A (en) | 1994-03-03 |
CA2141842A1 (en) | 1994-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69333287D1 (de) | Neuartige glykoformen als lösliche komplement-rezeptoren | |
HUT63063A (en) | Process for producing antibodies against cd44 cell surface glycoprotein and immunosuppressant pharmaceutical compositions comprising same | |
GR3007096T3 (de) | ||
KR100206481B1 (en) | Galenic form for ocular administration and process for the preparation of same | |
MY111196A (en) | Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma | |
UA42747C2 (uk) | Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту | |
MY109143A (en) | Sulfonamido-and sulfonamidocarbonylpyridine 2-carboxamides and their pyridine-n-oxides, process for their preparation and their use as pharmaceuticals | |
EP0154344A3 (en) | Antiviral pharmaceutical preparations and methods for their use | |
AU6989094A (en) | Compositions and methods for treating cancer and hyperproliferative disorders | |
AU7690596A (en) | Anti-CD6 monoclonal antibodies and their uses | |
ITMI922331A0 (it) | Uso di paratormone suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto protermine ed in generale per il trattamento della gestazione | |
GR3006815T3 (de) | ||
CA2094347A1 (en) | A method of producing a factor viii preparation | |
IT9067434A0 (it) | Procedimento per migliorare l'efficacia terapeutica di corticosteroidi liposolubili e composizione per l'attuazione di tale procedimento | |
CA2062047A1 (en) | Fusion proteins for prodrug activation, the preparation and use thereof | |
EP0336368A3 (en) | N2-(1-carboxy-3-phenylpropyl)-l-lysine derivative and process of producing lysinopril using the compound | |
AU2456888A (en) | Monoclonal antibodies specific for HIV and hybridomas for their production | |
EP1199361A3 (de) | Glycoprotein HormonRezeptor Moleküle. Ihre Verwendungen | |
EP0478689A4 (en) | Human monoclonal antibodies to hiv-1 mn? gp 120 | |
IT9020020A0 (it) | "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono | |
AU4959193A (en) | High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus | |
IE840977L (en) | Pharmaceutical preparations | |
IT8921513A0 (it) | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmacuetiche che li contengono. | |
AU680836B2 (en) | Human monoclonal antibodies to human immunodeficiency virus | |
TW372873B (en) | A novel anti-neoplastic cytokine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: CELLDEX THERAPEUTICS,INC. (N. D. GES.D.STAATES, US |